CRTHF (CARsgen Therapeutics Holdings) Piotroski F-Score: 5 (As of Jul. 08, 2026) — 25% Above Median


CRTHF CARsgen Therapeutics Holdings Ltd CRTHF
24 GF Score
Price $2.08
! 3 Warning Signs
View Full Analysis

What is CARsgen Therapeutics Holdings Piotroski F-Score?

CARsgen Therapeutics Holdings CRTHF 24 Piotroski F-Score is 5 as of Jul. 08, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates CRTHF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,330 Biotechnology companies, CARsgen Therapeutics Holdings ranks better than 84.96% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

CARsgen Therapeutics Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for CARsgen Therapeutics Holdings's Piotroski F-Score or its related term are showing as below:

CRTHF' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 5

During the past 7 years, the highest Piotroski F-Score of CARsgen Therapeutics Holdings was 5. The lowest was 2. And the median was 4.

CARsgen Therapeutics Holdings  (OTCPK:CRTHF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


CARsgen Therapeutics Holdings Piotroski F-Score Related Terms


CARsgen Therapeutics Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for CARsgen Therapeutics Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings Piotroski F-Score Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 5.00 4.00 2.00 3.00 5.00

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 0.00 3.00 0.00 5.00

CRTHF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's Piotroski F-Score falls into.


CRTHF
24GF Score
CARsgen Therapeutics Holdings Ltd CRTHF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was $-13.89 Mil.
Cash Flow from Operations was $-33.64 Mil.
Revenue was $17.84 Mil.
Gross Profit was $11.35 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (229.79 + 183.459) / 2 = $206.6245 Mil.
Total Assets at the begining of this year (Dec24) was $229.79 Mil.
Long-Term Debt & Capital Lease Obligation was $6.86 Mil.
Total Current Assets was $167.27 Mil.
Total Current Liabilities was $29.17 Mil.
Net Income was $-109.62 Mil.

Revenue was $5.42 Mil.
Gross Profit was $2.03 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (316.128 + 229.79) / 2 = $272.959 Mil.
Total Assets at the begining of last year (Dec23) was $316.13 Mil.
Long-Term Debt & Capital Lease Obligation was $18.23 Mil.
Total Current Assets was $210.18 Mil.
Total Current Liabilities was $34.89 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

CARsgen Therapeutics Holdings's current Net Income (TTM) was -13.89. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

CARsgen Therapeutics Holdings's current Cash Flow from Operations (TTM) was -33.64. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-13.894/229.79
=-0.0604639

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-109.623/316.128
=-0.34676776

CARsgen Therapeutics Holdings's return on assets of this year was -0.0604639. CARsgen Therapeutics Holdings's return on assets of last year was -0.34676776. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

CARsgen Therapeutics Holdings's current Net Income (TTM) was -13.89. CARsgen Therapeutics Holdings's current Cash Flow from Operations (TTM) was -33.64. ==> -33.64 <= -13.89 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=6.863/206.6245
=0.03321484

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=18.225/272.959
=0.06676827

CARsgen Therapeutics Holdings's gearing of this year was 0.03321484. CARsgen Therapeutics Holdings's gearing of last year was 0.06676827. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=167.266/29.171
=5.73398238

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=210.182/34.888
=6.02447833

CARsgen Therapeutics Holdings's current ratio of this year was 5.73398238. CARsgen Therapeutics Holdings's current ratio of last year was 6.02447833. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

CARsgen Therapeutics Holdings's number of shares in issue this year was 552.061. CARsgen Therapeutics Holdings's number of shares in issue last year was 552.875. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=11.351/17.842
=0.63619549

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.025/5.415
=0.37396122

CARsgen Therapeutics Holdings's gross margin of this year was 0.63619549. CARsgen Therapeutics Holdings's gross margin of last year was 0.37396122. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=17.842/229.79
=0.07764481

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=5.415/316.128
=0.01712914

CARsgen Therapeutics Holdings's asset turnover of this year was 0.07764481. CARsgen Therapeutics Holdings's asset turnover of last year was 0.01712914. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+1+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

CARsgen Therapeutics Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
CARsgen Therapeutics Holdings (CRTHF) has a Piotroski F-Score of 5 as of Jul. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CARsgen Therapeutics Holdings and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, CARsgen Therapeutics Holdings' Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, CARsgen Therapeutics Holdings ranks #200 out of 1330 companies in the Biotechnology industry, placing it in the top 15%.
Is CARsgen Therapeutics Holdings' Piotroski F-Score too high?
CARsgen Therapeutics Holdings' current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. CARsgen Therapeutics Holdings' value of 5 is 66.7% above this industry median. Based on the distribution chart, CARsgen Therapeutics Holdings ranks #200 out of 1330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARsgen Therapeutics Holdings ranks #200 out of 1330 companies for Piotroski F-Score. This places CARsgen Therapeutics Holdings in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. CARsgen Therapeutics Holdings' value of 5 is 66.7% above this benchmark. Historically, CARsgen Therapeutics Holdings' own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, CARsgen Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,330 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CARsgen Therapeutics Holdings's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CARsgen Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARsgen Therapeutics Holdings's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current Piotroski F-Score of 5. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 66.7% above the Biotechnology industry median of 3.00. CARsgen Therapeutics Holdings' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current Piotroski F-Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARsgen Therapeutics Holdings Business Description

Other Exchanges 02171:Hong Kong
Address No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
24GF Score

Get the complete analysis for CRTHF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price